Adams Helen C. 4

What Happened
Helen C. Adams, a director of Immix Biopharma (IMMX), received equity awards on 2026-05-22: 6,250 restricted stock units (RSUs) and a derivative award covering 12,500 shares (reported as a stock option). Both awards are reported with an acquisition price of $0.00 (typical for granted equity); total awarded shares = 18,750.

Key Details

• Transaction date: 2026-05-22; Form 4 filed 2026-05-29.
• Reported price: $0.00 for both the RSUs and the derivative award (grant reported, not an open-market purchase).
• Vesting (footnotes):
  • RSUs (6,250): vest in full on the earlier of the one-year anniversary of the grant or the date of the Issuer’s 2027 annual meeting, subject to continued service.
  • Stock option (12,500): vests in substantially equal monthly installments over the 12 months following grant, with any remaining unvested portion vesting on the 2027 annual meeting if that occurs earlier, subject to continued service.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No indication in the filing that shares were sold or exercised immediately.

Context
These awards are standard director compensation and will vest over time as described; they are different from purchases or sales and do not by themselves indicate immediate insider buying or selling intent. The derivative portion is a stock option subject to vesting; any future exercise would be reported separately.